genetically engineered cell therapy expressing CD40L (Bristol Myers Squibb)

N/A

Report date: 2025/01/26 19:27:09

Base Information

Drug Namegenetically engineered cell therapy expressing CD40L (Bristol Myers Squibb)
Drug Alias NameCD40 costimulator (Bristol Myers Squibb)CD40 costimulator (cytoDRiVE) (Obsidian)
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 agonists
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesObsidian Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb Company
Inactive CompaniesObsidian Therapeutics Inc
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A